Trials / Completed
CompletedNCT02370303
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
A Pilot Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 23 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.
Detailed description
The plan is to collect both blood and tumor samples from the patient's lung cancer in order to validate this technology in detecting circulating tumor cells. The investigators will also obtain a postoperative blood sample to see if there is a decrease in the overall circulating tumor cell measurement once the tumor has been surgically removed.
Conditions
- Lung Cancer
- Lung Neoplasms
- Cancer of Lung
- Cancer of the Lung
- Neoplasms, Lung
- Neoplasms, Pulmonary
- Pulmonary Cancer
- Pulmonary Neoplasms
- Carcinoma, Non-small-cell Lung
- Adenocarcinoma
- Squamous Cell Carcinoma
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2016-07-09
- Completion
- 2016-07-09
- First posted
- 2015-02-24
- Last updated
- 2018-03-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02370303. Inclusion in this directory is not an endorsement.